Literature DB >> 8573312

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

J P Allison1, A A Hurwitz, D R Leach.   

Abstract

One of the major goals of tumor immunotherapy is the induction of tumor-specific T-cell responses that will be effective in eradicating disseminated tumors. Emerging information on the role of costimulatory molecules in T-cell activation offers several new strategies for enhancing antitumor responses, including the induction of expression of costimulatory molecules on tumor cells, enhancement of the presentation of transferred tumor antigen by host antigen-presenting cells, and ex vivo antigen priming of autologous antigen-presenting cells.

Entities:  

Mesh:

Year:  1995        PMID: 8573312     DOI: 10.1016/0952-7915(95)80077-8

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  35 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.

Authors:  M C Gong; J B Latouche; A Krause; W D Heston; N H Bander; M Sadelain
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 3.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

4.  Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.

Authors:  Jillian H Hurst
Journal:  J Clin Invest       Date:  2015-09-08       Impact factor: 14.808

5.  Association between the CD28 IVS3 +17T>C (rs3116496) polymorphism and cancer susceptibility: a meta-analysis involving 8,843 subjects.

Authors:  Sheng Zhang; Yafeng Wang; Heping Jiang; Chao Liu; Haiyong Gu; Shuchen Chen; Mingqiang Kang; Weifeng Tang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

6.  CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses.

Authors:  H Voigt; D Schrama; A O Eggert; C S Vetter; K Müller-Blech; H M Reichardt; M H Andersen; J C Becker; F Lühder
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

7.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 8.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 9.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

Review 10.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.